MONTREAL, QUEBEC -- (MARKET WIRE) -- November 02, 2006 -- Ambrilia Biopharma Inc.(TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today that the findings of an extensive study conducted in collaboration with Dr. Dharam Ramnani, Laboratory Director at the Virginia Urology Pathology Laboratory, Richmond, Virginia, with its PSP94 (Prostate Secretory Protein of 94 amino acids) immunoassay for the diagnosis and prognosis of prostate cancer, were published in the October 15th issue of Clinical Cancer Research (Vol. 12, pp. 6018 - 6022).
